Biodesix announces impactful clinical data on the primary immune response (pir) test at the iaslc 2022 therapies of lung cancer meeting

Boulder, colo.--(business wire)---- $bdsx #patientsfirst--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced impactful data on the primary immune response (pir) test at the iaslc 2022 targeted therapies of lung cancer meeting. in this body of work, the pir test provided two classifications of pir-not resistant and pir-resistant predictive of likely response to immune checkpoint inhibitors (icis). the data showed that the biodesix pir test was
BDSX Ratings Summary
BDSX Quant Ranking